J&JPRD receives FDA Complete Response Letter for ceftobiprole

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot [...]

Meda expands collaboration with Etypharm for Axorid

Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks.

Competitive intelligence on Egypt’s pharmaceuticals and healthcare industry

Research and Markets has announced the addition of the “Egypt Pharmaceuticals and Healthcare Report Q1 2010″ report to their offering.

Significant limitations in new Ginkgo biloba study published in JAMA, says ABC

New research findings published this week on a standardized Ginkgo biloba extract are very limited and the public should focus on the well-documented cognitive and cardiovascular benefits of ginkgo, said the American Botanical Council (ABC), an independent nonprofit research and education organization.

CRN stands by Ginkgo biloba’s effectiveness in improving cognitive function

“It is important to put this study into context and to remember that there is a large body of previously published evidence, which suggests that Ginkgo biloba may help improve cognitive impairment in older adults. There are also additional ongoing clinical trials, the results of which may address some of the limitations of the current [...]

Ginkgo biloba does not slow rate of cognitive decline in older adults

Older adults who used the herbal supplement Ginkgo biloba for several years did not have a slower rate of cognitive decline compared to adults who received placebo, according to a study in the December 23/30 issue of JAMA.

NPA Responds To Quality Accounts Consultation, UK

The NPA (National Pharmacy Association) has expressed concern over the level of detail which PCTs need to submit for their Quality Accounts and how this could impact on community pharmacy…

Rising Pharmacy Graduate Numbers A Problem, Australia

Concerns raised by the Australian Medical Association over the lack of funding and resources to adequately train medical students have been echoed by the Pharmaceutical Society of Australia…

Prices Of Medicines Hit All-time Low, UK

The UK has dropped to bottom of the official league table comparing the price of medicines across Europe, a Government report has revealed. For the first time, the UK lags behind Austria, Belgium, Finland, France, Germany, Ireland, Italy, Netherlands, Spain and Sweden…